SEC Comment Letter 0000000000-25-002044 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: Feb. 21, 2025 · CIK: 0001671584 · Accession: 0000000000-25-002044
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284969
Letter
February 21, 2025 Marvin White Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-3 Filed February 14, 2025 File No. 333-284969 Dear Marvin White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Sean Donahue, Esq.
Show Raw Text
February 21, 2025
Marvin White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-3
Filed February 14, 2025
File No. 333-284969
Dear Marvin White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Sean Donahue, Esq.